Positive top-line results in second Phase III trial of ZX008 in Dravet syndrome

12 July 2018

Today, USA-based CNS-focused biotechZogenix (Nasdaq: ZGNX) announced positive top-line results from its second Phase III trial (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of Dravet syndrome, a rare form of childhood epilepsy.

Result findings are consistent with data reported from Phase III Study 1, announced in 2017, and the latest news sent the company’s shares soaring more than 17% to $54.27 by mid-morning trading, having leapt as much as 26%.

UK cannabinoid drug specialist GW Pharmaceuticals’ Epidiolex (cannabidiol) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome was approved by the Food and Drug Administration on June 25 this year, though this comes with the Drug Enforcement Administration (DEA) now having to review Epidiolex because of its potential for abuse before it can launch.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK